Ex-Ferring Exec Says He Had Rival's Drug Innovation First

Law360 (July 13, 2020, 11:19 PM EDT) -- Ferring's former chief scientific officer for urology on Monday testified in a New York federal bench trial, held via Zoom, that rival drugmaker Serenity's co-founder's "alleged" invention of a nighttime urination medication was based on the Ferring scientist's prior discoveries.

Ferring Pharmaceuticals is seeking to invalidate two Serenity Pharmaceuticals patents relating to the use of the anti-diuretic compound desmopressin, and Serenity has counterclaimed that Ferring's drug Nocdurna infringes those patents.

During the second week of the patent showdown being held remotely before Chief Judge Colleen McMahon of the Southern District of New York, Ferring called to the virtual stand Dr. Jens...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!